Grundinformationen
- Standard-SMILES
Cc1cnc(C(=O)O)c[n+]1[O-]- InChIKey
DJQOOSBJCLSSEY-UHFFFAOYSA-N- Summenformel
- C6H6N2O3
- Durchschnittliche Molmasse
- 154,12 g/mol
- Monoisotopische Masse
- 154,03784205
Überblick
5-methyl-4-oxido-2-pyrazin-4-iumcarboxylic acid is a pyrazinecarboxylic acid.
Namen und Bezeichner
- Bevorzugter Name
- Acipimox
- IUPAC
- 5-methyl-4-oxidopyrazin-4-ium-2-carboxylic acid
- Lokaler Name
- Acipimox
- Englischer Name
- Acipimox
- Summenformel
- C6H6N2O3
- Molmasse
- 154.12
Namen und Synonyme
Weitere Namen anzeigen
Datenbank-Bezeichner
- CAS
51037-30-0- PubChem CID
- 5310993
- DTXSID
DTXSID2046202- ChEMBL
CHEMBL345714- ChEBI
CHEBI:94688- UNII
- K9AY9IR2SD
- EC Number
- 256-928-3
- Nikkaji
- J10.290C
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- -1
- Polarare Oberfläche (TPSA)
- 75,7 Ų
- H-Brücken-Donoren
- 1
- H-Brücken-Akzeptoren
- 4
- Frei drehbare Bindungen
- 1
- Schwere Atome
- 11
- Formalladung
- 0
- Komplexität
- 162
Experimentelle und physikochemische Eigenschaften
Drugs
Pharmaceuticals -> Antilipidemics
Pharmaceuticals -> Listed in ZINC15
Physikochemische Eigenschaften
- Schmelzpunkt
- 177 · 177-180 °C
- Siedepunkt
- 539 · 539.0±45.0 °C(Predicted)
- Dichte
- 1.44 · 1.44±0.1 g/cm3(Predicted)
- storage temp.
- 2 · Inert atmosphere,2-8°C
- Löslichkeit
- Soluble in methanol, water (100 mM), DMSO (100 mM), ethanol (<1 mg/ml at 25° C), and 1 M NH4OH (1 mg/ml).
- Aggregatzustand
- Solid
- pka
- 2.8 · 2.80±0.10(Predicted)
- Farbe
- Yellow
- Merck
- 14 · 14,111
- InChI
- InChI=1S/C6H6N2O3/c1-4-2-7-5(6(9)10)3-8(4)11/h2-3H,1H3,(H,9,10)
- InChIKey
- DJQOOSBJCLSSEY-UHFFFAOYSA-N
- SMILES
- C1(C(O)=O)N=CC(C)=[N+]([O-])C=1
- CAS Datenbank
- 51037 · 51037-30-0(CAS DataBase Reference)
- EPA chemische Informationen
- 5 · Pyrazinecarboxylic acid, 5-methyl-, 4-oxide (51037-30-0)
Sicherheit und Regulatorisches
GHS-Klassifizierung
GHS Classification
This chemical does not meet GHS hazard criteria for 41.7% (30 of 72) of reports.
Warning
H319 (58.3%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
P264+P265, P280, P305+P351+P338, and P337+P317 (click each P-code to see the statement)
Aggregated GHS information provided per 72 reports by companies from 3 notifications to the ECHA C&L Inventory.
Gefahrenhinweise
Sicherheitsdaten
- wgk
- 3
- hs_code
- 2933.99.8290
- RTECS-Nr.
- UQ2453000
- risk_code
- 36
- Toxizität
- LD50 orally in mice: 3500 mg/kg (Ambrogi)
- hazard_code
- Xi
- safety_code
- 26
- Speicherklasse
- 11 - Combustible Solids
Chemie und Industrie
Pharmakologische Informationen
ATC Code
C10AD06
C - Cardiovascular system
QC - Cardiovascular system
Anwendungen
BeschreibungAcipimox is a nicotinic acid derivate that structurally related to nicotinic acid. Like nicotinic acid, lowers lipids effectively, but unlike nicotinic acid, acipimox is longer acting and therefore much less prone to produce free fatty acid rebounding. It is usually employed in man in the therapy of hypertriglyceridemia. In addition to its lipid lowering activity, it produces a beneficial elevation of the anti-atherogenic high density lipoprotein subfraction, HDL2. Acipimox is recommended as a lipid-lowering agent to treat hyperlipidemia in patients with noninsulin dependent diabetes mellitus.
VerwendenAcipimox is a long-acting antilipemic agent and used for the treatment of hyperlipoproteinemias, in particular hypertriglyceridemias, and as adjunctive therapy for affecting cholesterol metabolism.
Darstellung
synthetischeSynthesis of acipimox: Under cooling and stirring, 78 g of maleic anhydride was dissolved in a solution of 60 ml of chloroform, and 40 ml of 30% hydrogen peroxide was added. After 2 h, 4.8 g of 5-Methyl-2-pyrazinecarboxylic acid was added, and the temperature was kept at 0-5 °C for 2 d. The maleic acid was filtered off. Concentrate to a small volume, add ethyl acetate, and filter to obtain 1.1 g of acipimox, the melting point of which is 178-180 °C.
Vor- und nachgelagerte Produkte
Vorgelagerte Rohstoffe
Anbieter50 Anbieter
Zugehörige Reaktionen
Verknüpfte Notizen
Wird geladen…